Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pesampator
- Development stage
- Phase 2
- Lead developer
- Biogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pesampator (developmental code names BIIB104 and PF-04958242) is a first-in-class small molecule positive allosteric modulator (PAM) of the AMPA receptor, an ionotropic glutamate receptor. It was originally developed by Pfizer and later by Biogen for the treatment of cognitive impairment associated with schizophrenia. The drug enhances synaptic transmission by potentiating AMPA receptor function, which is thought to improve working memory and other cognitive functions. Pesampator underwent multiple phase 1 trials demonstrating safety and tolerability in healthy volunteers and individuals with schizophrenia on stable antipsychotic regimens. However, development for both schizophrenia-related cognitive impairment and age-related sensorineural hearing loss was discontinued due to insufficient efficacy[1][4][5][7].
- Other names
- pesampatorPF-4958242PF4958242PF 4958242
02
Targets
AMPAR (AMPA receptor)SLC6A9 (Glycine transporter type 1)
Beyond the preview
Go deeper on pesampator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pesampator.